Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.
Discovery Park opened its doors for the East Kent Science Jamboree, hosting a record-breaking 1,500 children from 51 Kent schools for a two-day science spectacular.
Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.
Present Made, Eddington, is leading the way with Cambridge’s first purpose-built, large-scale corporate letting scheme – a pioneering development that brings 21st-century executive living to one of the UK’s most dynamic science and technology hubs.
A new residential development in North Cambridge is offering science and technology businesses a ready-made solution to one of the city’s most pressing challenges: housing professional staff within easy reach of major employment hubs.
From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.
Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.
Coulter Partners successfully completed a search assignment for Melt&Marble and is pleased to announce the placement of Tue Hodal as its first Chief Technology Officer (CTO).
At BIA’s recent Start-up festival, we caught up with Mark Bartlett, CEO of StoreGene, to learn more about his journey, what drives him, and his advice for founders navigating the world of genomics and startups.
Strategic partnership between Medicines Discovery Catapult and the Crick ensures continued national delivery of KQ Labs, a leading accelerator programme for early-stage innovators.
